Anti-CATB/ CTSB/ APPS functional antibody
Anti-CATB/ CTSB/ APPS functional antibody for cell culture, ELISA & in-vivo assay
Go to CTSB/CTSB products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-T61746-Ab-1/ GM-Tg-hg-T61746-Ab-2 | Anti-Human CTSB monoclonal antibody | Human |
GM-Tg-rg-T61746-Ab-1/ GM-Tg-rg-T61746-Ab-2 | Anti-Rat CTSB monoclonal antibody | Rat |
GM-Tg-mg-T61746-Ab-1/ GM-Tg-mg-T61746-Ab-2 | Anti-Mouse CTSB monoclonal antibody | Mouse |
GM-Tg-cynog-T61746-Ab-1/ GM-Tg-cynog-T61746-Ab-2 | Anti-Cynomolgus/ Rhesus macaque CTSB monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-T61746-Ab-1/ GM-Tg-felg-T61746-Ab-2 | Anti-Feline CTSB monoclonal antibody | Feline |
GM-Tg-cang-T61746-Ab-1/ GM-Tg-cang-T61746-Ab-2 | Anti-Canine CTSB monoclonal antibody | Canine |
GM-Tg-bovg-T61746-Ab-1/ GM-Tg-bovg-T61746-Ab-2 | Anti-Bovine CTSB monoclonal antibody | Bovine |
GM-Tg-equg-T61746-Ab-1/ GM-Tg-equg-T61746-Ab-2 | Anti-Equine CTSB monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-T61746-Ab-1/ GM-Tg-hg-T61746-Ab-2; GM-Tg-rg-T61746-Ab-1/ GM-Tg-rg-T61746-Ab-2; GM-Tg-mg-T61746-Ab-1/ GM-Tg-mg-T61746-Ab-2; GM-Tg-cynog-T61746-Ab-1/ GM-Tg-cynog-T61746-Ab-2; GM-Tg-felg-T61746-Ab-1/ GM-Tg-felg-T61746-Ab-2; GM-Tg-cang-T61746-Ab-1/ GM-Tg-cang-T61746-Ab-2; GM-Tg-bovg-T61746-Ab-1/ GM-Tg-bovg-T61746-Ab-2; GM-Tg-equg-T61746-Ab-1/ GM-Tg-equg-T61746-Ab-2 |
Products Name | Anti-CTSB monoclonal antibody |
Format | mab |
Target Name | CTSB |
Protein Sub-location | Secreted Protein/Potential Cytokines |
Category of antibody | FACS/Biofunctional Antibody, Therapeutics Target antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD). |
Tag | Fc |
Products description | Pre-made anti-CTSB benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | GM-Tg-g-T61746-Ag-1 | Recombinant multi-species CATB/ CTSB/ APPS protein |
ORF Viral Vector | vGMLV000311 | human CTSB Lentivirus particle |
ORF Viral Vector | pGMLV000311 | human CTSB Lentivirus plasmid |
ORF Viral Vector | pGMAD000496 | Norway rat Ctsb Adenovirus plasmid |
ORF Viral Vector | pGMLPm001493 | mouse Ctsb Lentivirus plasmid |
ORF Viral Vector | vGMAD000496 | Norway rat Ctsb Adenovirus particle |
ORF Viral Vector | vGMLPm001493 | mouse Ctsb Lentivirus particle |
Target information
Target ID | GM-T61746 |
Target Name | CTSB |
Gene ID | 1508,13030,64529,100424758,486077,101084873,281105,100060963 |
Gene Symbol and Synonyms | APPS,CATB,CB,CPSB,CTSB,KWE,RECEUP |
Uniprot Accession | P07858,P00787,P07688 |
Uniprot Entry Name | CATB_HUMAN,CATB_RAT,CATB_BOVIN |
Protein Sub-location | Secreted Protein/Potential Cytokines |
Category | Therapeutics Target |
Disease | Malignant neoplasm of bladder, IgA glomerulonephritis, tumors |
Gene Ensembl | ENSG00000164733 |
Target Classification | N/A |
The target: CTSB, gene name: CTSB, also named as APPS, CPSB, RECEUP. This gene encodes a member of the C1 family of peptidases. Alternative splicing of this gene results in multiple transcript variants. At least one of these variants encodes a preproprotein that is proteolytically processed to generate multiple protein products. These products include the cathepsin B light and heavy chains, which can dimerize to form the double chain form of the enzyme. This enzyme is a lysosomal cysteine protease with both endopeptidase and exopeptidase activity that may play a role in protein turnover. It is also known as amyloid precursor protein secretase and is involved in the proteolytic processing of amyloid precursor protein (APP). Incomplete proteolytic processing of APP has been suggested to be a causative factor in Alzheimer's disease, the most common cause of dementia. Overexpression of the encoded protein has been associated with esophageal adenocarcinoma and other tumors. Both Cathepsin B and Cathepsin L are involved in the cleavage of the spike protein from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) upon its entry to the human host cell. Multiple pseudogenes of this gene have been identified. [provided by RefSeq, Sep 2020].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.